Acute effects of high-density lipoproteins: Biochemical basis and clinical findings

Current Opinion in Cardiology

Volumn 23, Issue 4, 2008, Pages 379-385

  Chiesa, Giulia ^a   Parolini, Cinzia ^a   Sirtori, Cesare R ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

apoA I; apoA I mimetic peptides; apoA IMilano; Cardiovascular disease; High density lipoproteins

Indexed keywords

CHOLESTEROL; CREATINE KINASE; FAS ANTIGEN; HIGH DENSITY LIPOPROTEIN; PHOSPHOLIPID;

ANTIOXIDANT ACTIVITY; ATHEROMA; ATHEROSCLEROSIS; DRUG ACTIVITY; HEART FUNCTION; NONHUMAN; PRIORITY JOURNAL; RABBIT; REMISSION; REVIEW;

ANIMALS; APOLIPOPROTEIN A-I; ATHEROSCLEROSIS; HUMANS; LIPOPROTEINS, HDL; PEPTIDES; PHOSPHATIDYLINOSITOLS;

EID: 44649143930     PISSN: 02684705     EISSN: None     Source Type: Journal    
DOI: 10.1097/HCO.0b013e3283007ccd     Document Type: Review

References (60)

1. Gordon T, Castelli WP, Hjortland MC, et al. High density lipoprotein as a protective factor against coronary heart disease: the Framingham Study. Am J Med 1977; 62:707-714.
2. Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk: the PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996; 124 (Suppl):S11-S20.
3. Paszty C, Maeda N, Verstuyft J, Rubin EM. Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J Clin Invest 1994; 94:899-903.
4. Spady DK. Reverse cholesterol transport and atherosclerosis regression. Circulation 1999; 100:576-578.
5. Rothblat GH, de la Llera-Moya M, Atger V, et al. Cell cholesterol efflux: integration of old and new observations provides new insights. J Lipid Res 1999; 40:781-796.
6. Bonnefont-Rousselot D, Therond P, Beaudeux JL, et al. High density lipoproteins (HDL) and the oxidative hypothesis of atherosclerosis. Clin Chem Lab Med 1999; 37:939-948.
7. Naqvi TZ, Shah PK, Ivey PA, et al. Evidence that high-density lipoprotein cholesterol is an independent predictor of acute platelet-dependent thrombus formation. Am J Cardiol 1999; 84:1011-1017.
8. Saku K, Ahmad M, Glas-Greenwalt P, Kashyap ML. Activation of fibrinolysis by apolipoproteins of high density lipoproteins in man. Thromb Res 1985; 39: 1-8.
9. Calabresi L, Gomaraschi M, Franceschini G. Endothelial protection by high-density lipoproteins: from bench to bedside. Arterioscler Thromb Vasc Biol 2003; 23:1724-1731.
10. Badimon JJ, Badimon L, Fuster V. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit. J Clin Invest 1990; 85:1234-1241.
11. Miyazaki A, Sakuma S, Morikawa W, et al. Intravenous injection of rabbit apolipoprotein A-I inhibits the progression of atherosclerosis in cholesterol-fed rabbits. Arterioscler Thromb Vasc Biol 1995; 15:1882-1888.
12. Dimayuga P, Zhu J, Oguchi S, et al. Reconstituted HDL containing human apolipoprotein A-1 reduces VCAM-1 expression and neointima formation following periadventitial cuff-induced carotid injury in apoE null mice. Biochem Biophys Res Commun 1999; 264:465-468.
13. Cockerill GW, Huehns TY, Weerasinghe A, et al. Elevation of plasma highdensity lipoprotein concentration reduces interleukin-1-induced expression of E-selectin in an in vivo model of acute inflammation. Circulation 2001; 103:108-112.
14. Nicholls SJ, Dusting GJ, Cutri B, et al. Reconstituted high-density lipoproteins inhibit the acute pro-oxidant and proinflammatory vascular changes induced by a periarterial collar in normocholesterolemic rabbits. Circulation 2005; 111:1543-1550.
15. Puranik R, Bao S, Nobecourt E, et al. Low dose apolipoprotein A-I rescues carotid arteries from inflammation in vivo. Atherosclerosis 2008; 196:240-247. The study shows that a single, low dose of lipid-free apoA-I decreases neutrophil infiltration and inhibits neutrophil and endothelial cell activation in normocholesterolemic rabbits undergoing periarterial collar implantation.
16. Calabresi L, Rossoni G, Gomaraschi M, et al. High-density lipoproteins protect isolated rat hearts from ischemia-reperfusion injury by reducing cardiac tumor necrosis factor-alpha content and enhancing prostaglandin release. Circ Res 2003; 92:330-337.
17. Rossoni G, Gomaraschi M, Berti F, et al. Synthetic high-density lipoproteins exert cardioprotective effects in myocardial ischemia/reperfusion injury. J Pharmacol Exp Ther 2004; 308:79-84.
18. Sumi M, Sata M, Miura S, et al. Reconstituted high-density lipoprotein stimulates differentiation of endothelial progenitor cells and enhances ischemia-induced angiogenesis. Arterioscler Thromb Vasc Biol 2007; 27:813-818. Intravenous injections of sHDL containing human apoA-I directly stimulated endothelial progenitor cell differentiation and enhanced ischemia-induced angiogenesis in a mouse model of hindlimb ischemia.
19. Paternò R, Ruocco A, Postiglione A, et al. Reconstituted high-density lipoprotein exhibits neuroprotection in two rat models of stroke. Cerebrovasc Dis 2004; 17:204-211.
20. Carlson LA. Effect of a single infusion of recombinant human proapolipoproteinA-I liposomes (synthetic HDL) on plasma lipoproteins in patients with low high density lipoprotein cholesterol. Nutr Metab Cardiovasc Dis 1995; 5: 85-91.
21. Eriksson M, Carlson LA, Miettinen TA, Angelin B. Stimulation of fecal steroid excretion after infusion of recombinant proapolipoprotein A-I. Potential reverse cholesterol transport in humans. Circulation 1999; 100:594-598.
22. Nanjee MN, Crouse JR, King JM, et al. Effects of intravenous infusion of lipid-free apo A-I in humans. Arterioscler Thromb Vasc Biol 1996; 16:1203-1214.
23. Nanjee MN, Doran JE, Lerch PG, Miller NE. Acute effects of intravenous infusion of ApoA1/phosphatidylcholine discs on plasma lipoproteins in humans. Arterioscler Thromb Vasc Biol 1999; 19:979-989.
24. Nanjee MN, Cooke CJ, Garvin R, et al. Intravenous apoA-I/lecithin discs increase prebeta-HDL concentration in tissue fluid and stimulate reverse cholesterol transport in humans. J Lipid Res 2001; 42:1586-1593.
25. Spieker LE, Sudano I, Hurlimann D, et al. High-density lipoprotein restores endothelial function in hypercholesterolemic men. Circulation 2002; 105:1399-1402.
26. Bisoendial RJ, Hovingh GK, Levels JH, et al. Restoration of endothelial function by increasing high-density lipoprotein in subjects with isolated low high-density lipoprotein. Circulation 2003; 107:2944-2948.
27. Tardif JC, Gregoire J, L'Allier PL, et al. Effects of reconstituted high-density lipoprotein infusions on coronary atherosclerosis: a randomized controlled trial. JAMA 2007; 297:1675-1682. In this study the efficacy of sHDL containing human apoA-I in atherosclerosis regression was tested in coronary patients. Plaque volumes were assessed by the IVUS methodology. Short-term infusions of apoA-I-based sHDL promoted a significant reduction of atheroma volume vs baseline.
28. Sethi AA, Amar M, Shamburek RD, Remaley AT. Apolipoprotein AI mimetic peptides: possible new agents for the treatment of atherosclerosis. Curr Opin Investig Drugs 2007; 8:201-212.
29. Garber DW, Datta G, Chaddha M, et al. A new synthetic class A amphipathic peptide analogue protects mice from diet-induced atherosclerosis. J Lipid Res 2001; 42:545-552.
30. Navab M, Anantharamaiah GM, Reddy ST, et al. Apolipoprotein A-I mimetic peptides. Arterioscler Thromb Vasc Biol 2005; 25:1325-1331.
31. Navab M, Anantharamaiah GM, Hama S, et al. Oral administration of an Apo A-I mimetic Peptide synthesized from D-amino acids dramatically reduces atherosclerosis in mice independent of plasma cholesterol. Circulation 2002; 105:290-292.
32. Li X, Chyu KY, Faria Neto JR, et al. Differential effects of apolipoprotein A-I-mimetic peptide on evolving and established atherosclerosis in apolipoprotein E-null mice. Circulation 2004; 110:1701-1705.
33. Navab M, Anantharamaiah GM, Hama S, et al. D-4F and statins synergize to render HDL antiinflammatory in mice and monkeys and cause lesion regression in old apolipoprotein E-null mice. Arterioscler Thromb Vasc Biol 2005; 25:1426-1432.
34. Shah PK, Chyu KY. Apolipoprotein A-I mimetic peptides: potential role in atherosclerosis management. Trends Cardiovasc Med 2005; 15:291-296.
35. Bloedon LT, Dunbar RL, Duffy D, et al. Oral administration of the apolipoprotein A-I mimetic peptide D-4F in humans with CHD improves HDL antiinflammatory function after a single dose. Circulation 2006; 114:288.
36. Remaley AT, Thomas F, Stonik JA, et al. Synthetic amphipathic helical peptides promote lipid efflux from cells by an ABCA1-dependent and an ABCA1-independent pathway. J Lipid Res 2003; 44:828-836.
37. Gomaraschi M, Calabresi L, Rossoni G, et al. Anti-inflammatory and cardioprotective activities of synthetic high-density lipoprotein containing apolipoprotein A-I mimetic peptides. J Pharmacol Exp Ther 2008; 324:776-783. In an isolated rat heart model of ischemia-reperfusion injury, both the apoA-I-mimetic peptide L37pA and its D-stereoisomer D37pA, complexed with phospholipids, significantly reduced postischemic cardiac contractile dysfunction compared with controls and their protective effect was comparable to that of sHDL containing human apoA-I.
38. Weisgraber KH, Bersot TP, Mahley RW, et al. A-Imilano apoprotein. Isolation and characterization of a cysteine-containing variant of the A-I apoprotein from human high density lipoproteins. J Clin Invest 1980; 66:901-907.
39. Gualandri V, Franceschini G, Sirtori CR, et al. AIMilano apoprotein identification of the complete kindred and evidence of a dominant genetic transmission. Am J Hum Genet 1985; 37:1083-1097.
40. Sirtori CR, Calabresi L, Franceschini G, et al. Cardiovascular status of carriers of the apolipoprotein A-I(Milano) mutant: the Limone sul Garda study. Circulation 2001; 103:1949-1954.
41. Franceschini G, Calabresi L, Chiesa G, et al. Increased cholesterol efflux potential of sera from ApoA-IMilano carriers and transgenic mice. Arterioscler Thromb Vasc Biol 1999; 19:1257-1262.
42. Favari E, Gomaraschi M, Zanotti I, et al. A unique protease-sensitive high density lipoprotein particle containing the apolipoprotein A-I(Milano) dimer effectively promotes ATP-binding Cassette A1-mediated cell cholesterol efflux. J Biol Chem 2007; 282:5125-5132.
43. Bielicki JK, Oda MN. Apolipoprotein A-I(Milano) and apolipoprotein A-I(Paris) exhibit an antioxidant activity distinct from that of wild-type apolipoprotein A-I. Biochemistry 2002; 41:2089-2096.
44. Ameli S, Hultgardh-Nilsson A, Cercek B, et al. Recombinant apolipoprotein A-I Milano reduces intimal thickening after balloon injury in hypercholesterolemic rabbits. Circulation 1994; 90:1935-1941.
45. Soma MR, Donetti E, Parolini C, et al. Recombinant apolipoprotein A-IMilano dimer inhibits carotid intimal thickening induced by perivascular manipulation in rabbits. Circ Res 1995; 76:405-411.
46. Kaul S, Rukshin V, Santos R, et al. Intramural delivery of recombinant apolipoprotein A-IMilano/phospholipid complex (ETC-216) inhibits in-stent stenosis in porcine coronary arteries. Circulation 2003; 107:2551-2554.
47. Shah PK, Nilsson J, Kaul S, et al. Effects of recombinant apolipoprotein A-IMilano on aortic atherosclerosis in apolipoprotein E-deficient mice. Circulation 1998; 97:780-785.
48. Shah PK, Yano J, Reyes O, et al. High-dose recombinant apolipoprotein A-IMilano mobilizes tissue cholesterol and rapidly reduces plaque lipid and macrophage content in apolipoprotein e-deficient mice. Potential implications for acute plaque stabilization. Circulation 2001; 103:3047-3050.
49. Chiesa G, Di Mario C, Colombo N, et al. Development of a lipid-rich, soft plaque in rabbits, monitored by histology and intravascular ultrasound. Atherosclerosis 2001; 156:277-287.
50. Chiesa G, Monteggia E, Marchesi M, et al. Recombinant apolipoprotein A-IMilano infusion into rabbit carotid artery rapidly removes lipid from fatty streaks. Circ Res 2002; 90:974-980.
51. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA 2003; 290:2292-2300.
52. Nicholls SJ, Tuzcu EM, Sipahi I, et al. Relationship between atheroma regression and change in lumen size after infusion of apolipoprotein A-I Milano. J Am Coll Cardiol 2006; 47:992-997.
53. Parolini C, Marchesi M, Lorenzon P, et al. Dose-related effects of repeated ETC-216 (recombinant apolipoprotein A-IMilano/1-palmitoyl-2-oleoyl phosphatidylcholine complex) administrations on rabbit lipid-rich soft plaques: in vivo assessment by IVUS and MRI. J Am Coll Cardiol 2008; 51:1098-1103. In this very recent experimental study, rabbits with established atherosclerotic lesions were treated with five graded doses of ETC-216. A dose-related effect on plaque volume, ranging from a lower progression to a marked regression, was evaluated in vivo by IVUS and MRI. Moreover, two administrations of the highest dose were adequate to determine a significant plaque regression.
54. Marchesi M, Booth EA, Rossoni G, et al. Apolipoprotein A-IMilano/POPC complex attenuates postischemic ventricular dysfunction in the isolated rabbit heart. Atherosclerosis 2008; 197:572-578. This ex-vivo study on a rabbit model of global ischemia showed the ability of ETC-216 to protect myocardium at least in part through antioxidative mechanisms.
55. Marchesi M, Booth EA, Davis T, et al. Apolipoprotein A-IMilano and 1-palmitoyl-2-oleoyl phosphatidylcholine complex (ETC-216) protects the in vivo rabbit heart from regional ischemia-reperfusion injury. J Pharmacol Exp Ther 2004; 311:1023-1031.
56. Navab M, Hama S, Hough G, Fogelman AM. Oral synthetic phospholipid (DMPC) raises high-density lipoprotein cholesterol levels, improves high-density lipoprotein function, and markedly reduces atherosclerosis in apolipoprotein E-null mice. Circulation 2003; 108:1735-1739.
57. Burgess JW, Neville TA, Rouillard P, et al. Phosphatidylinositol increases HDL-C levels in humans. J Lipid Res 2005; 46:350-355.
58. Rodrigueza WV, Klimuk SK, Pritchard PH, Hope MJ. Cholesterol mobilization and regression of atheroma in cholesterol-fed rabbits induced by large unilamellar vesicles. Biochim Biophys Acta 1998; 1368:306-320.
59. Brewer HB Jr. Focus on high-density lipoproteins in reducing cardiovascular risk. Am Heart J 2004; 148:S14-S18.
60. Nicholls SJ, Tuzcu EM, Sipahi I, et al. Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA 2007; 297:499-508.